ACS Chem Biol. 2011 May 20;6(5):419-24. doi: 10.1021/cb1003866. Epub 2011 Mar 7.
Histone deacetylases (HDACs) and histone acetyl-transferases (HATs) are universal regulators of eukaryotic transcriptional activity and emerging therapeutic targets for human diseases. Here we describe the generation of isotope-labeled deacetylation and acetylation reporters for simultaneous NMR readouts of multiple deacetylation and acetylation reactions at different histone H4 sites. The site preferences of two prototypic histone deacetylases (Sir2.1 and HDAC8) and two acetyl-transferases (HAT1 and p300/CBP) were studied in intramolecular competition assays. We identify a previously ill-defined acetylation site, lysine 20 of histone H4, as a preferred target of three of theses enzymes. In situ analyses of endogenous deacetylation reactions at H4 sites in HeLa nuclear extracts point to abundant HDAC activities in human cellular environments.
组蛋白去乙酰化酶(HDACs)和组蛋白乙酰转移酶(HATs)是真核转录活性的通用调节剂,也是人类疾病的新兴治疗靶点。在这里,我们描述了同位素标记的去乙酰化和乙酰化报告分子的产生,用于同时进行多个组蛋白 H4 不同位点的去乙酰化和乙酰化反应的 NMR 读出。在分子内竞争测定中研究了两种典型的组蛋白去乙酰化酶(Sir2.1 和 HDAC8)和两种乙酰转移酶(HAT1 和 p300/CBP)的位点偏好性。我们确定了一个以前定义不明确的乙酰化位点,即组蛋白 H4 的赖氨酸 20,是这三种酶的首选靶标。在 HeLa 核提取物中内源性组蛋白 H4 位点去乙酰化反应的原位分析表明,在人类细胞环境中存在丰富的 HDAC 活性。